Best Practices for Implementing Dual Endothelin Angiotensin Receptor Antagonist Therapeutics in Patients with IgA Nephropathy (IgAN) - (Jun 18, 2024 - Jun 17, 2025)

Best Practices for Implementing Dual Endothelin Angiotensin Receptor Antagonist Therapeutics in Patients with IgA Nephropathy (IgAN) is organized by AcademicCME.

Description:
IgA nephropathy (IgAN) involves the abnormal deposition of IgA antibodies in the kidneys, leading to chronic inflammation and progressive renal damage. It is the most common primary glomerulonephritis globally, with variable clinical outcomes and a significant impact on renal function in some patients. IgAN typically manifests in young to middle-aged adults, with a slight male predominance in some populations. There are notable geographical differences in prevalence, with higher rates observed in Asian countries compared to Western countries.

The diagnosis of IgAN must be confirmed by kidney biopsy showing mesangial IgA deposits with or without other histological changes. Treatment strategies focus on controlling blood pressure, reducing proteinuria, and managing progression with medications like ACE inhibitors or ARBs. Immunosuppressive therapy may be considered in certain cases with progressive disease. Novel strategies for management include the DEARA approach: Dual Endothelin and Angiotensin II Receptor Antagonists, which offer a targeted therapy to reduce proteinuria.

In this series of programs, our expert faculty will review the epidemiology, pathophysiology, genetics, and supportive treatment form IgAN, including new specific therapies. We will also discuss team management—from PCP to nephrologis —and supportive patient education to achieve continuity of care and adherence to optimal treatment strategies in IgAN.

Learning Objectives:

• Review the epidemiology, pathophysiology, and genetics of IgAN